Compass Therapeutics (NASDAQ:CMPX) Now Covered by Analysts at Craig Hallum

Craig Hallum started coverage on shares of Compass Therapeutics (NASDAQ:CMPX) in a report published on Friday, Marketbeat reports. The brokerage issued a buy rating and a $15.00 price objective on the stock.

Several other equities analysts have also recently commented on CMPX. Citigroup began coverage on shares of Compass Therapeutics in a report on Wednesday, December 3rd. They set an “outperform” rating on the stock. Citizens Jmp began coverage on Compass Therapeutics in a research report on Wednesday, December 3rd. They issued a “market outperform” rating and a $10.00 target price on the stock. William Blair initiated coverage on Compass Therapeutics in a research note on Monday, January 5th. They set an “outperform” rating for the company. Raymond James Financial restated an “outperform” rating and issued a $9.00 price objective on shares of Compass Therapeutics in a report on Tuesday, January 6th. Finally, Leerink Partners upgraded Compass Therapeutics to a “strong-buy” rating in a research note on Wednesday, November 26th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $13.00.

Compass Therapeutics Stock Performance

Shares of CMPX opened at $6.28 on Friday. The company has a market capitalization of $1.12 billion, a PE ratio of -13.96 and a beta of 1.46. The company’s 50 day moving average price is $5.67 and its 200 day moving average price is $4.49. Compass Therapeutics has a 52 week low of $1.33 and a 52 week high of $6.88.

Institutional Investors Weigh In On Compass Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Marshall Wace LLP bought a new stake in shares of Compass Therapeutics in the 4th quarter valued at approximately $6,786,000. The Manufacturers Life Insurance Company boosted its stake in Compass Therapeutics by 21.6% in the 4th quarter. The Manufacturers Life Insurance Company now owns 40,325 shares of the company’s stock valued at $217,000 after buying an additional 7,164 shares in the last quarter. Stifel Financial Corp bought a new stake in Compass Therapeutics in the fourth quarter valued at $129,000. Rafferty Asset Management LLC raised its stake in Compass Therapeutics by 113.8% during the fourth quarter. Rafferty Asset Management LLC now owns 151,743 shares of the company’s stock worth $815,000 after acquiring an additional 80,784 shares in the last quarter. Finally, Birchview Capital LP lifted its holdings in shares of Compass Therapeutics by 82.5% during the fourth quarter. Birchview Capital LP now owns 1,592,938 shares of the company’s stock valued at $8,554,000 after acquiring an additional 720,000 shares during the period. 68.43% of the stock is owned by institutional investors and hedge funds.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.